SCHEMBL7527451

SCHEMBL7527451

CCOP(=O)(O)c1cc(-c2ccc(CBr)cc2)ccc1OC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.39
▸ CYP17A1 P05093 1/20 0.36
▸ POLB P06746 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ NR1H4 Q96RI1 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ ALOX5 P09917 1/20 0.34
▸ GABRA1 P14867 1/20 0.34
▸ GABRB2 P47870 1/20 0.34
▸ PTPN1 P18031 1/20 0.34
▸ PTPN6 P29350 1/20 0.34
▸ PTPN11 Q06124 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ S1PR1 P21453 3/20 0.33
▸ SMPD1 P17405 2/20 0.33
▸ S1PR2 O95136 1/20 0.33
▸ S1PR3 Q99500 1/20 0.33
▸ LPAR2 Q9HBW0 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ MGLL Q99685 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7188009 0.86 ALDH1A1 (0.47) ALDH1A1PTPN1PTPN6PTPN11S1PR1
SCHEMBL7181991 0.86 CFD (0.42) ALDH1A1POLBALOX5PTPN1PTPN6
SCHEMBL7527206 0.85 ALDH1A1 (0.41) ALDH1A1L3MBTL1LMNA
SCHEMBL7186784 0.83 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2PTPN1PTPN6PTPN11
SCHEMBL7593841 0.80 SRC (0.34) ALDH1A1
SCHEMBL7527444 0.80 HPGD (0.39) ALDH1A1CYP17A1SMN1; SMN2NR1H4L3MBTL1
SCHEMBL7184273 0.76 PLA2G2D (0.40) ALDH1A1POLBL3MBTL1PTPN1LMNA
SCHEMBL7193757 0.72 ALDH1A1 (0.50) ALDH1A1PTPN1PTPN6PTPN11S1PR1
SCHEMBL7188821 0.72 CFD (0.41) ALDH1A1SMN1; SMN2LMNA
SCHEMBL16868513 0.71 ALDH1A1 (0.68) ALDH1A1POLBSMN1; SMN2L3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6486141-B2 TREATING OR PREVENTING PTP-1B MEDIATED DISEASES, INCLUDING DIABETES, OBESITY, AND DIABETES-RELATED CONDITIONS. MERCK FROSST CANADA & CO. (CA) 2002-11-26 — — US disclosed
EP-1244677-A1 PHOSPHONIC ACID BIARYL DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B (PTP-1B) MERCK FROSST CANADA INC. (CA) 2002-10-02 — — EP disclosed
US-20020052346-A1 Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B) MERCK FROSST CANADA LTD. (CA) 2002-05-02 — — US disclosed
WO-2001046203-A1 PHOSPHONIC ACID BIARYL DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B (PTP-1B) MERCK FROSST CANADA & CO. (CA) 2001-06-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052346-A1 Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B) PTPRO, PPM1B, PTPA ALDH1A1 600/4885CYP17A1 834/4885POLB 2457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback